Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016
Metrics: PDF 1370 views | HTML 2747 views | ?
Zhennan Yuan1, Libin Xu1, Zhenguo Zhao1, Songfeng Xu1, Xinxin Zhang1, Ting Liu1, Shuguang Zhang1 and Shengji Yu1
1Department of Orthopaedics, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Shengji Yu, email: [email protected]
Keywords: malignant peripheral nerve sheath tumor, clinicopathological features, prognosis, Ki67, S-100
Received: December 20, 2016 Accepted: June 18, 2017 Published: July 04, 2017
Objective: To investigate the clinicopathological features and prognosis of malignant peripheral nerve sheath tumors (MPNST).
Results: A total of 159 patients with MPNST were enrolled in the study. The ratio of male to female was 1.04 to 1. The median age was 40 (range: 5–76) years at the time of diagnosis. The 3- and 5-year overall survival rates were 50.0% and 43.0%, respectively. The median follow-up period was 31.0 (range: 2.0–199.0) months. Multivariate analysis showed that AJCC stage and S-100 were independent factors affecting overall survival (p < 0.05 for both). 3- and 5-year tumor-free survival rates for 140 completely resected patients were 40.0% and 34.0%, respectively. Multivariate analysis showed that AJCC stage, S-100 and Ki67 staining were independent factors of tumor-free survival (p < 0.05 for all).
Materials and Methods: The clinical data of MPNST patients who were treated at Cancer Institute and Hospital, Chinese Academy of Medical Science from January 1999 to January 2016 was retrospectively reviewed.
Conclusions: MPSNT is a highly aggressive tumor with poor prognosis and this study may be useful for prognostic assessment and management decisions. This had been largest documented retrospective study of MPSNT among Chinese populations. Some characteristics were different from those of foreign populations which may suggest the specificity of Chinese patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.